1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Exec Chat: Abbott Invests In Outreach To Underrepresented Populations

 
• By Reed Miller

Jennifer Jones-McMeans, Divisional Vice President of Global Clinical Affairs at Abbott’s vascular device business, talked to Medtech Insight about her company’s ongoing efforts to diversify patient enrollment in clinical trials by communicating more effectively and compassionately with people in traditionally underrepresented demographic groups.

• Source: Shutterstock

As part of its long-term effort to improve access to its technology, Abbott is trying to reduce barriers to participation in clinical trials, especially for groups of people who have traditionally been underrepresented in clinical trials and underserved by medical technology.

About 40% of the US population is a member of an historically underrepresented demographic group, but multiple studies have shown that members of these populations are underrepresented in clinical trials...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By Marion Webb

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By Marion Webb

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.

More from R&D